Inogen (INGN) Aktie Kurs
Inogen Kurs
De seneste 14 år voksede Inogens omsætning med 19,0 % årligt og nåede 348,67 Mio. USD. Indtjening pr. aktie er vokset med 58,1 % om året de seneste 7 år. For Inogen er nettoavance på -6,5 % ned i forhold til -1,8 % for et par år siden. Konsensus 12-måneders kursmål for Inogen er 13,26 USD, cirka over kursen med 109,5 %. Af 8 analytikere anbefaler 7 køb — den samlede vurdering er Køb.
Inogen aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Inogen aktie og aktieanalyse
Hyppigt stillede spørgsmål om Inogen-aktien
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen Inc is primarily active in the medical device industry.
The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.
Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.
Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.
Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.
Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 13,26 USD for Inogen-aktien (median: 13,26 USD), svarende til +109,5 % i forhold til seneste kurs. Konsensus bygger på 8 analytikervurderinger.
8 analytikere vurderer i øjeblikket Inogen-aktien: 7 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Inogen genererer omsætning på 356,42 Mio. USD og indtjening pr. aktie på -0,75 USD.
Omregnet til den aktuelle valutakurs handles Inogen-aktien til 5,66 EUR (6,33 USD).
Inogen-aktien (INGN) er noteret på 4 børser, herunder: NASDAQ (INGN), SIX (Zürich) (6IO.SW), Frankfurt (6IO.F), Düsseldorf (6IO.DU).
Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.
forventet-omsætningen for Inogen er 356,42 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Inogen er -20,32 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Inogen er i øjeblikket -8,46. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Inogen-aktien.
Pris-til-salgs-forholdet (P/S) for Inogen er i øjeblikket 0,48. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Inogen-aktien.
AlleAktien-kvalitetsscore for Inogen er 1/10.
ISIN for Inogen er US45780L1044. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Inogen er A1XB32. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Inogen er INGN. Tickersymbolet bruges til at handle Inogen-aktier på børsen.
Inogen aktie
Inogen Peer Group
Inogen Ticker
Inogen FIGI
Alle fundamentale data om Inogen i deep dive
Vores aktieanalyse af Inogen-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Inogen. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: